

ENDOCRINE MANIFESTATIONS OF PAEDIATRIC INTRACRANIAL GERM CELL TUMOUR: FROM DIAGNOSIS TO LONG-TERM FOLLOW-UP

Cristina PARTENOPE¹, Gabriella POZZOBON¹, Fernando CARCELLER², Assunta ALBANESE²

- 1. San Raffaele Hospital, Milan, Italy
- 2. Royal Marsden Hospital, Sutton, United Kingdom

The ROYAL MARSDEN



INTRODUCTION

Endocrinopathies are common features of intracranial germ cell tumours (IC-GCTs), either as presenting symptoms caused by tumour itself or as side effects of treatments.

AIM


Examine the development of endocrine dysfunctions in a cohort of paediatric patients with IC-GCTs at diagnosis and during follow up.

METHOD


- 55 patients from two European tertiary centres followed in the last 25 years
- Diabetes insipidus (DI), growth hormone deficiency (GHD), central hypothyroidism, adrenal insufficiency (AI), precocious puberty (PP), hypogonadotrophic hypogonadism (HH)
- The prevalence of endocrine sequelae was compared to survival rates.


RESULTS


- 67.3% males
- Median age: 12 years (range 1–17.9)
- Median follow-up from diagnosis: 78.9 months (range 0.5-249.9)
- Patients underwent biopsy (83.6%), gross tumour resection (14.5%), chemotherapy (76.4%) and radiotherapy (90.9%).
- 63.6% were germinomas. 10.9% were metastatic at diagnosis
- At tumour diagnosis, 28/55 patients (50.9%) displayed endocrine dysfunctions. At the last follow up visit, 37/55 patients (67.3%) displayed endocrine dysfunctions.





Overall survival (OS) rate was 80%. No statistical difference in OS was found between patients with and without endocrine sequelae (p=0.37).














Among baseline characteristics only pineal tumour location was significantly negatively associated with the development of long-term endocrine complications.

CONCLUSIONS

- Endocrine disorders were frequent in patients with IC-GCTs at diagnosis.
- Additional endocrinopathies can occur decades after completion of treatments.
- Although survival rate was not affected by the presence of endocrinopathies in our cohort, close lifelong surveillance is mandatory.

REFERENCES

- Takada A, et al.: J Neurosurg Pediatr 2018 Nov 23;23(3):317-324
- 2. Chemaitilly W, Sklar CA. Horm Res Paediatr 2019 2019;91(2):74-82.
- 3. Odagiri K, et al.: Int J Radiat Oncol Biol Phys 2012 Nov 1;84(3):632-8.

